MDWD
MediWound Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
MediWound Ltd.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
No changes.
No thesis.
Annual filing, covered
20-F parsed · Mar 5 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Mar 5 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Largest filed tie
0
filed ties
Same SIC code · 6
Same SEC industry code: Definium Therapeutics, Inc., Usana Health Sciences Inc, Niagen Bioscience, Inc. and 3 more; of MediWound Ltd.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Definium Therapeutics, Inc., Usana Health Sciences Inc, Niagen Bioscience, Inc. and 3 more; of MediWound Ltd.'s 6 closest co-movers, none share that code.
—
MediWound Ltd.
13.55
+0.05 · +0.37%
Expected move
No implied move.
News
| Manager | Value | % base | |
|---|---|---|---|
| Investor | $12.8M | 14.92% | 0.00% |
| Yelin Lapidot | $11.1M | 12.97% | −0.61% |
| Rosalind | $11.0M | 12.81% | 0.00% |
| T. Rowe Price | $9.4M | 10.97% | −9.69% |
| BlackRockindex-like | $7.7M | 9.00% | +17.97% |
| Manager | Value | % base | |
|---|---|---|---|
| Investor | $12.8M | 14.92% | 0.00% |
| Yelin Lapidot | $11.1M | 12.97% | −0.61% |
| Rosalind | $11.0M | 12.81% | 0.00% |
| T. Rowe Price | $9.4M | 10.97% | −9.69% |
| BlackRockindex-like | $7.7M | 9.00% | +17.97% |